SCHEMBL23319931

SCHEMBL23319931

COc1ccc(-c2ccc(Oc3[nH]nnc3C(=O)O)cc2OC)c(OC)n1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALPL P05186 1/20 0.42
PRKAG1 P54619 1/20 0.41
PRKAA1 Q13131 1/20 0.41
PRKAB1 Q9Y478 1/20 0.41
POLB P06746 2/20 0.40
TDP1 Q9NUW8 1/20 0.40
PLAU P00749 1/20 0.39
ERN1 O75460 1/20 0.38
HAO1 Q9UJM8 8/20 0.38
PDE10A Q9Y233 2/20 0.36
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
CYP1A2 P05177 1/20 0.34
METAP2 P50579 1/20 0.34
ADORA3 P0DMS8 1/20 0.34
POLQ O75417 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31166182 1.00 ALPL (0.42) ALPLPRKAG1PRKAA1PRKAB1POLB
SCHEMBL23319947 0.86 POLB (0.42) ALPLPRKAG1PRKAA1PRKAB1POLB
SCHEMBL29967937 0.86 POLB (0.42) ALPLPRKAG1PRKAA1PRKAB1POLB
SCHEMBL31166249 0.83 HAO1 (0.44) ALPLPRKAG1PRKAA1PRKAB1ERN1
SCHEMBL23319906 0.83 HAO1 (0.44) ALPLPRKAG1PRKAA1PRKAB1ERN1
SCHEMBL23319999 0.80 ALPL (0.43) ALPLPRKAG1PRKAA1PRKAB1POLB
SCHEMBL23319889 0.75 HAO1 (0.54) PRKAG1PRKAA1PRKAB1HAO1MEN1
SCHEMBL25463830 0.74 RCE1 (0.40) ALPLERN1HAO1MEN1KMT2A
SCHEMBL21296956 0.74 HAO1 (0.52) ALPLPRKAG1PRKAA1PRKAB1HAO1
SCHEMBL25464365 0.73 HAO1 (0.40) ALPLPRKAG1PRKAA1PRKAB1ERN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230143491-A1 TRIAZOLE GLYCOLATE OXIDASE INHIBITORS PHOENIX TISSUE REPAIR, INC. 2023-05-11 US disclosed
US-20230143491-A1 TRIAZOLE GLYCOLATE OXIDASE INHIBITORS PHOENIX TISSUE REPAIR, INC. 2023-05-11 US disclosed
US-20230143491-A1 TRIAZOLE GLYCOLATE OXIDASE INHIBITORS PHOENIX TISSUE REPAIR, INC. 2023-05-11 US disclosed
US-20210403439-A1 TRIAZOLE GLYCOLATE OXIDASE INHIBITORS VENTHERA, INC. 2021-12-30 US disclosed
EP-3817816-A1 TRIAZOLE GLYCOLATE OXIDASE INHIBITORS Orfan Biotech Inc. (US) 2021-05-12 EP disclosed
CN-112399873-A Triazole glycolate oxidase inhibitor 奥凡生物科技公司 2021-02-23 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230143491-A1 TRIAZOLE GLYCOLATE OXIDASE INHIBITORS XDH, DUOX1, PNPO ALPL 652/4885PRKAG1 2945/4885PRKAA1 2067/4885
US-20210403439-A1 TRIAZOLE GLYCOLATE OXIDASE INHIBITORS XDH, DUOX1, PNPO ALPL 652/4885PRKAG1 2945/4885PRKAA1 2067/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.